Compare Kinross Gold Corporation (KGC) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Eli Lilly And Co — how do they compare? Kinross Gold Corporation trades at $23.74 (market cap $27.62B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 37.7× Kinross Gold Corporation's market cap, and Kinross Gold Corporation pays the higher dividend (0.69%). Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Eli Lilly And Co for 93 Days on average.
| KGC | LLY | |
|---|---|---|
Market Cap | $27.62B | $1.04T |
Volume | 6,347,266 | 3,064,878 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $1.28K |
52-Week Low | $22.47 | $799.57 |
Typical Hold Time | 53 Days | 93 Days |
Enterprise Value | $25.70B | $1.09T |
Dividend Yield | 0.69% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold Corporation (KGC) trades at $23.34, up 0.69% today, with strong fundamentals including a P/E of 8.87 and robust profitability metrics. Recent earnings have consistently beaten expectations, though technical indicators signal bearish momentum. The company reported $7.05B revenue and $2.39B net income for 2025, with cash flow from operations reaching $3.76B. However, production guidance cuts for 2026-2027 have pressured the stock, offset by increased shareholder returns targeting 50% of free cash flow.
KGC presents a mixed outlook: attractive valuation and earnings growth support upside to the $38.80 consensus price target, but near-term risks include operational setbacks at key mines and ongoing legal investigations. The stock's bearish technical trend and rising costs warrant caution, though institutional buying and high analyst buy ratings (58.63%) indicate underlying confidence in long-term value.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
